Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Emocog Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The prosecution activity is currently limited to this single matter. This concentration means that the outcome of the company's active patent efforts depends on the findings of a specific administrative group. Such a narrow focus allows the applicant to dedicate resources to a specific technical dialogue. The alignment of the technical subject matter within the specified group suggests a focused patenting strategy for the biotechnology technology.
EMILY ANN DARRIGRAND is the busiest examiner for the portfolio, managing 1 pending office action. Since there is only 1 distinct examiner, this person is responsible for all active prosecution. The 1 distinct art unit shows the technology is being reviewed by a single specialized biotechnology group. For the applicant, this suggests a focused prosecution environment where consistency in examiner communication is paramount. The limited scope of the current activity simplifies the management of the portfolio. This examiner handles the total active matters for the firm, ensuring that all feedback is filtered through a specific professional perspective.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DARRIGRAND, EMILY ANN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18242594 | PARKINSON'S DISEASE PREDICTION APPARATUS AND PARKINSON'S DISEASE PREDICTION METHOD | DARRIGRAND, EMILY ANN | — |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18242594 | PARKINSON'S DISEASE PREDICTION APPARATUS AND PARKINSON'S DISEASE PREDICTION METHOD | DARRIGRAND, EMILY ANN | 1686 | §101§102§103 | Non-Final OA | — | Pending | Sep 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEmocog Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emily Ann Darrigrand has the most, with 1 of Emocog Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
